Sign in
Taking peopleNo phase

Shortwave therapy compared with sham treatment for nerve damage from diabetes

Tests shortwave therapy against a sham device in people with diabetic peripheral neuropathy.

Key facts

Who runs it
Chongqing Medical University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Shortwave Intervention for Diabetic Peripheral Neuropathy.
Status
Recruiting
People taking part
202 people, planned
Started
20 May 2026
Expected to end
20 May 2027
Type of study
Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • Short-Wave Diathermy
  • Placebo treatment group
Record updated
18 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with diabetes who have nerve damage in the legs and feet (diabetic peripheral neuropathy). It tests shortwave heat therapy against a fake (sham) treatment.

Age
18 to 85 years
Sex
All sexes
Disease stage
Nerve symptoms such as numbness, tingling, burning, cold or pain that started at or after the diabetes diagnosis. Signs on nerve tests may or may not be present. People must be able to complete the TCSS nerve assessment.
Earlier treatment
Nerve symptoms did not improve after adequate treatment with mecobalamin and other medicines.

Main reasons for not taking part

  • Nerve damage from other causes, such as lower back spine problems, vitamin B12 deficiency, alcohol or Guillain-Barré syndrome
  • Bleeding disorders or cancer
  • Leg amputation below the knee, skin damage or infection at the treatment site, metal implants or a pacemaker
  • Severe heart, liver or kidney problems (e.g., eGFR < 15 ml/min/1.73m²), or memory and thinking problems that prevent cooperation
  • Pregnancy, breastfeeding or planning a pregnancy

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • 1. Aged 18-85 years, regardless of gender, with the ability to act independently
  • 2. Appearance of neuropathic symptoms or signs at the time of or after the diagnosis of diabetes, meeting the following criteria: presence of DPN symptoms (numbness, tingling, burning, cold, pain), with or without signs (abnormalities in any of ankle reflex, vibration sense, pinprick sensation, temperature sensation, or pressure sensation)
  • 3. Able to complete the TCSS assessment
  • 4. Understands the entire trial process, voluntarily participates in the study, and signs the informed consent form
  • 5. Patients who did not respond to adequate treatment with mecobalamin and other medications

Who cannot take part

  • 1. Peripheral neuropathy caused by other reasons (such as lumbar spine lesions, vitamin B12 deficiency, uncontrolled hypothyroidism, alcohol intoxication, drug neurotoxicity, Guillain-Barré syndrome, etc.)
  • 2. Hemorrhagic diseases, malignant tumors
  • 3. History of below-knee amputation
  • 4. Skin damage, infection at the treatment site, or presence of metal implants, pacemaker
  • 8. Combined severe psychiatric disorders
  • 9. Other conditions assessed by the investigator that prevent completion of the trial
  • 5. Combined severe heart, liver, or kidney dysfunction (e.g., eGFR < 15 ml/min/1.73m²), or cognitive impairment preventing cooperation
  • 6. Pregnancy, breastfeeding, or planning pregnancy
  • 7. Participation in other interventional clinical trials within the past 3 months
  • 10. Poor compliance

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 85 years old?

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is a single-center, randomized, single-blind, sham-controlled clinical trial aimed at evaluating the efficacy and safety of shortwave therapy administered for five consecutive days in the treatment of diabetic peripheral neuropathy. The study plans to enroll 202 patients, who will be randomly assigned in a 1:1 ratio to either the shortwave therapy group (20 minutes daily for five consecutive days) or a sham treatment group with an identical appearance. The primary efficacy endpoint is the remission rate of the Toronto Clinical Scoring System score one month after treatment (a decrease of ≥1 point). Secondary endpoints include short-term efficacy, pain visual analog scale scores, quality of life scores, and safety indicators. The study hypothesizes that shortwave therapy can significantly improve neurological symptoms, with an expected remission rate of 65% in the treatment group and 20% in the control group, with the superiority margin set at 20%. This study will provide high-quality evidence-based medical evidence for the use of shortwave therapy in diabetic peripheral neuropathy.

The 2 groups in the trial

  • Placebo treatment groupSham treatment, for comparison

    Using devices that are completely identical in appearance, the treatment process, screen display, and sounds are the same as the active group, but the devices are specially modified and do not emit electromagnetic energy. To ensure the success of blinding, the skin temperature of the treatment area will be measured before and after treatment, but the specific values will not be disclosed to the subjects.

  • Shortwave therapy groupTreatment being tested

    Using the CJ270-I model shortwave therapy instrument from Nanjing Congjing Biological Machinery Co., Ltd. Patients took a sitting position, placed both lower limbs into the therapy instrument, adjusted the power to 250W, frequency to 27.12MHz, once daily, 20 minutes each time, for 5 consecutive days.

    Treatment: Short-Wave Diathermy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Shortwave Intervention for Diabetic Peripheral Neuropathy: A Randomized, Single-Blind, Sham-Controlled Trial(SIDPN)
Plain-language title
Shortwave therapy compared with sham treatment for nerve damage from diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT07625007, who can take part
Record updated
18 June 2026